Last reviewed · How we verify
Umbilical cord blood
Umbilical cord blood contains stem cells that may aid in tissue repair and regeneration.
Umbilical cord blood contains stem cells that may aid in tissue repair and regeneration. Used for Treatment of various conditions, including blood disorders, autoimmune diseases, and certain types of cancer.
At a glance
| Generic name | Umbilical cord blood |
|---|---|
| Also known as | UCB, cord blood, hematopoietic stem cells |
| Sponsor | Shandong Qilu Stem Cells Engineering Co., Ltd. |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action is not fully understood, but it is believed that the stem cells in umbilical cord blood may help to repair damaged tissues and promote healing. This may be particularly useful in the treatment of certain medical conditions.
Approved indications
- Treatment of various conditions, including blood disorders, autoimmune diseases, and certain types of cancer
Common side effects
- Graft-versus-host disease
- Infection
Key clinical trials
- Consequences of Antiangiogenic Factors Involved in Preeclampsia on Intra-uterine Growth Restricted Preterm Newborn
- Cord Blood Preptin Levels in Infants (NA)
- Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 (PHASE3)
- Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies (PHASE1)
- Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome (PHASE1, PHASE2)
- Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma (PHASE1)
- US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies (PHASE1, PHASE2)
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Umbilical cord blood CI brief — competitive landscape report
- Umbilical cord blood updates RSS · CI watch RSS
- Shandong Qilu Stem Cells Engineering Co., Ltd. portfolio CI